| Series Introduction |
|
iii | (2) |
| Preface |
|
v | (8) |
| Contributors |
|
xiii | |
| I. Clinical Features |
|
3 | (104) |
|
1. Skin Manifestations of Psoriasis and Eczematous Psoriasis: Maturation |
|
|
3 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2. Pustular Psoriasis: Generalized and Localized |
|
|
13 | (28) |
|
|
|
|
|
|
|
|
|
|
|
|
|
41 | (4) |
|
|
|
|
|
|
4. Scalp and Hair, Palms and Soles |
|
|
45 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5. Photosensitive Psoriasis |
|
|
59 | (6) |
|
|
|
|
|
|
|
|
|
|
|
6. Human Immunodeficiency Virus and Psoriasis |
|
|
65 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
75 | (22) |
|
|
|
|
|
|
|
|
|
|
|
8. Psychological Aspects of Psoriasis |
|
|
97 | (10) |
|
|
|
|
|
|
|
|
|
|
| II. Incidence and Genetics |
|
107 | (84) |
|
9. Epidemiology: Natural History and Genetics |
|
|
107 | (52) |
|
|
|
|
|
|
|
|
|
|
|
10. Psoriasis Type I and Type II as Subtypes of Nonpustular Psoriasis |
|
|
159 | (8) |
|
|
|
|
|
|
|
|
|
|
|
11. Population Genetics of Psoriasis |
|
|
167 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
177 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| III. Pathogenesis |
|
191 | (192) |
|
13. Overview of Immunology |
|
|
191 | (18) |
|
|
|
|
|
|
|
|
|
|
|
14. The Polymorphonuclear Leukocytes |
|
|
209 | (16) |
|
Peter C.M. van de Kerkhof |
|
|
|
|
|
15. Keratinocyte Abnormalities and Signaling Pathways |
|
|
225 | (22) |
|
|
|
|
|
|
16. Cell Proliferation Kinetics |
|
|
247 | (16) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
263 | (24) |
|
|
|
|
|
|
18. The Cell Membrane in Psoriasis |
|
|
287 | (28) |
|
|
|
|
|
|
|
|
|
|
|
19. Pathogenic Interactions of Keratinocytes and T Lymphocytes in Psoriasis |
|
|
315 | (14) |
|
|
|
|
|
|
|
|
329 | (12) |
|
|
|
|
|
|
21. Immunological Pathways in Psoriasis |
|
|
341 | (8) |
|
Christopher E.M. Griffiths |
|
|
|
|
|
22. Molecular and Immunological Aspects of Psoriasis |
|
|
349 | (8) |
|
|
|
|
|
|
|
|
|
|
|
23. Cytokine Abnormalities in the Epidermis |
|
|
357 | (16) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24. Anti-Infectious Therapy of Psoriasis |
|
|
373 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IV. Histology |
|
383 | (38) |
|
25. Neuropeptides and Neurogenic Inflammation in Psoriasis |
|
|
383 | (10) |
|
|
|
|
|
|
|
|
|
|
|
26. Neuropeptides and Psoriasis |
|
|
393 | (6) |
|
|
|
|
|
|
|
|
399 | (10) |
|
|
|
|
|
|
28. Histopathology and Electron Microscopy of Psoriasis |
|
|
409 | (12) |
|
|
|
|
|
|
Gundula M. Schaumburg-Lever |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| V. Topical Therapy |
|
421 | (108) |
|
29. Product Development for Psoriasis: Clinical Challenges and Opportunities |
|
|
421 | (14) |
|
|
|
|
|
|
30. Dithranol (Anthralin) |
|
|
435 | (18) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31. Topical Corticosteroids |
|
|
453 | (16) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
469 | (10) |
|
|
|
|
|
|
|
|
|
|
|
33. Ambulatory Treatment Centers: United States Experience |
|
|
479 | (4) |
|
|
|
|
|
|
|
|
|
|
|
34. Occlusive Therapy of Psoriasis |
|
|
483 | (6) |
|
|
|
|
|
|
35. Vitamin D: Rationale and Potential Mechanism of Action |
|
|
489 | (8) |
|
|
|
|
|
|
|
|
|
|
|
36. Vitamin D Analogues in the Treatment of Psoriasis |
|
|
497 | (10) |
|
|
|
|
|
|
|
|
|
|
|
37. Clinical Experience with Vitamin D Analogues |
|
|
507 | (4) |
|
|
|
|
|
|
|
|
|
|
|
38. Combination Therapies: Dovonex and Phototherapy |
|
|
511 | (8) |
|
|
|
|
|
|
|
|
|
|
|
39. Safety of and Skin Irritation with Vitamin D |
|
|
519 | (10) |
|
|
|
|
|
| VI. Phototherapy |
|
529 | (70) |
|
|
|
529 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
41. Oral Psoralen Photochemotherapy |
|
|
543 | (16) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
559 | (6) |
|
|
|
|
|
|
43. Topical PUVA and Bath PUVA |
|
|
565 | (12) |
|
|
|
|
|
|
|
|
577 | (10) |
|
|
|
|
|
|
45. Combination and Rotational Therapy for Psoriasis |
|
|
587 | (6) |
|
|
|
|
|
|
46. Climatotherapy of Psoriasis |
|
|
593 | (6) |
|
|
|
|
|
| VII. Systemic Therapy |
|
599 | (108) |
|
47. Systemic Corticosteroids |
|
|
599 | (4) |
|
|
|
|
|
|
|
|
|
|
|
48. Topical Corticosteroid Occlusion Therapy: Psoriasis |
|
|
603 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
609 | (22) |
|
|
|
|
|
|
|
|
|
|
|
|
|
631 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
637 | (4) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
52. Cyclosporin for the Treatment of Psoriasis |
|
|
641 | (18) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
53. Long-Term Use of Cyclosporin in Dermatology |
|
|
659 | (4) |
|
|
|
|
|
|
54. Clinical Use of Etretinate and Acitretin |
|
|
663 | (8) |
|
|
|
|
|
|
|
|
|
|
|
55. Acitretin and Etretinate: Strategy for Use and Long-Term Side Effects |
|
|
671 | (14) |
|
|
|
|
|
|
|
|
|
|
|
56. Clinical Pharmacology of Acitretin |
|
|
685 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
57. Retinoid Combinations |
|
|
697 | (10) |
|
|
|
|
|
|
|
|
|
|
| VIII. New Treatments and Innovations |
|
707 | (100) |
|
58. Bioengineering and Psoriasis |
|
|
707 | (8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
59. Pharmacological Models for Psoriasis Syndromes |
|
|
715 | (12) |
|
|
|
|
|
|
|
|
|
|
|
60. Psoriasis Small Plaque Assay for Assessment of Topical Drug Activity |
|
|
727 | (4) |
|
|
|
|
|
|
|
|
|
|
|
|
|
731 | (12) |
|
|
|
|
|
|
Roshantha A.S. Chandraratna |
|
|
|
|
|
62. Tacrolimus (FK506) in the Treatment of Psoriasis |
|
|
743 | (6) |
|
|
|
|
|
|
63. Clinical Use of Oral 1,25-Dihydroxyvitamin D3 (Calcitriol) for the Treatment of Psoriasis and Psoriatic Arthritis |
|
|
749 | (8) |
|
|
|
|
|
|
64. Photodynamic Therapy of Psoriasis |
|
|
757 | (4) |
|
|
|
|
|
|
|
|
|
|
|
65. Antithyroid Thioureylenes in Psoriasis |
|
|
761 | (8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
769 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
67. Purine Nucleoside Phosphorylase Inhibition: A Novel Therapy for Psoriasis |
|
|
781 | (8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
68. Potential Clinical Uses for Parathyroid Hormone-Related Peptide Analogues for Treating Psoriasis and Other Skin Disorders |
|
|
789 | (6) |
|
|
|
|
|
|
69. DAB389 IL-2: A Lymphocyte-Targeted Fusion Toxin |
|
|
795 | (6) |
|
|
|
|
|
|
70. Surgical Treatment of Psoriasis |
|
|
801 | (6) |
|
|
|
|
|
|
|
|
|
|
| IX. Patient Involvement in Psoriasis |
|
807 | (30) |
|
71. Nursing for Psoriasis |
|
|
807 | (8) |
|
|
|
|
|
|
72. Using Art Therapy in the Treatment of Psoriasis: A Pilot Study |
|
|
815 | (18) |
|
|
|
|
|
|
73. The National Psoriasis Organization: A Means to Educate and Advocate |
|
|
833 | (4) |
|
|
|
|
|
| Index |
|
837 | |
Shopping Cart
